These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16133800)

  • 1. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
    Macdonald JS; McCoy S; Whitehead RP; Iqbal S; Wade JL; Giguere JK; Abbruzzese JL
    Invest New Drugs; 2005 Oct; 23(5):485-7. PubMed ID: 16133800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
    Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
    J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
    J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
    Adjei AA; Mauer A; Bruzek L; Marks RS; Hillman S; Geyer S; Hanson LJ; Wright JJ; Erlichman C; Kaufmann SH; Vokes EE
    J Clin Oncol; 2003 May; 21(9):1760-6. PubMed ID: 12721252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
    Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H
    Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
    Heymach JV; Johnson DH; Khuri FR; Safran H; Schlabach LL; Yunus F; DeVore RF; De Porre PM; Richards HM; Jia X; Zhang S; Johnson BE
    Ann Oncol; 2004 Aug; 15(8):1187-93. PubMed ID: 15277257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
    Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
    Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
    Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
    Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
    Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.
    Rich TA; Winter K; Safran H; Hoffman JP; Erickson B; Anne PR; Myerson RJ; Cline-Burkhardt VJ; Perez K; Willett C
    Onco Targets Ther; 2012; 5():161-70. PubMed ID: 22977306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
    Venkatasubbarao K; Choudary A; Freeman JW
    Cancer Res; 2005 Apr; 65(7):2861-71. PubMed ID: 15805288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
    Rao S; Cunningham D; de Gramont A; Scheithauer W; Smakal M; Humblet Y; Kourteva G; Iveson T; Andre T; Dostalova J; Illes A; Belly R; Perez-Ruixo JJ; Park YC; Palmer PA
    J Clin Oncol; 2004 Oct; 22(19):3950-7. PubMed ID: 15459217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
    Kurzrock R; Albitar M; Cortes JE; Estey EH; Faderl SH; Garcia-Manero G; Thomas DA; Giles FJ; Ryback ME; Thibault A; De Porre P; Kantarjian HM
    J Clin Oncol; 2004 Apr; 22(7):1287-92. PubMed ID: 15051776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
    Lara PN; Law LY; Wright JJ; Frankel P; Twardowski P; Lenz HJ; Lau DH; Kawaguchi T; Gumerlock PH; Doroshow JH; Gandara DR
    Anticancer Drugs; 2005 Mar; 16(3):317-21. PubMed ID: 15711184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
    Johnston SR; Hickish T; Ellis P; Houston S; Kelland L; Dowsett M; Salter J; Michiels B; Perez-Ruixo JJ; Palmer P; Howes A
    J Clin Oncol; 2003 Jul; 21(13):2492-9. PubMed ID: 12829668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
    Zhang M; Jiang D
    Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyl transferase inhibitors for patients with lung cancer.
    Johnson BE; Heymach JV
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4254s-4257s. PubMed ID: 15217969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.